Investors focused on the Medical space have likely heard of Amgen (AMGN - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
Amgen is one of 756 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. AMGN is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AMGN's full-year earnings has moved 2.14% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, AMGN has moved about 19.20% on a year-to-date basis. At the same time, Medical stocks have gained an average of 11.82%. This shows that Amgen is outperforming its peers so far this year.
Looking more specifically, AMGN belongs to the Medical - Biomedical and Genetics industry, which includes 280 individual stocks and currently sits at #99 in the Zacks Industry Rank. On average, this group has gained an average of 2.43% so far this year, meaning that AMGN is performing better in terms of year-to-date returns.
AMGN will likely be looking to continue its solid performance, so investors interested Medical stocks should continue to pay close attention to the company.